|Mr. Bradley C. Robinson||CEO, Pres & Director||325k||N/A||1969|
|Mr. Simon Brewer||Chief Financial & Accounting Officer||62.5k||N/A||1979|
|Mr. Paul S. Evans||Chief Operating Officer||N/A||N/A||1963|
|Mr. Eric K. Olson||Exec. VP||76.67k||N/A||1963|
|Timothy W. Lacy||Pres||N/A||N/A||1969|
Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps). The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
Predictive Technology Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.